X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5810) 5810
Magazine Article (12) 12
Book Chapter (9) 9
Newsletter (6) 6
Book Review (4) 4
Dissertation (2) 2
Publication (2) 2
Conference Proceeding (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5615) 5615
ticlopidine - analogs & derivatives (4788) 4788
male (3384) 3384
female (3106) 3106
ticlopidine - therapeutic use (2812) 2812
middle aged (2672) 2672
aged (2651) 2651
clopidogrel (2609) 2609
platelet aggregation inhibitors - therapeutic use (2585) 2585
ticlopidine - adverse effects (2508) 2508
platelet aggregation inhibitors - adverse effects (2275) 2275
aspirin (1779) 1779
cardiac & cardiovascular systems (1745) 1745
ticlopidine - administration & dosage (1720) 1720
treatment outcome (1654) 1654
platelet aggregation inhibitors - administration & dosage (1515) 1515
aspirin - therapeutic use (1465) 1465
drug therapy, combination (1299) 1299
risk factors (1162) 1162
percutaneous coronary intervention (1118) 1118
aspirin - adverse effects (988) 988
stents (909) 909
aspirin - administration & dosage (852) 852
antiplatelet therapy (844) 844
time factors (836) 836
peripheral vascular disease (828) 828
ticlopidine (792) 792
abridged index medicus (763) 763
platelet aggregation - drug effects (739) 739
adult (728) 728
thrombosis (712) 712
prospective studies (693) 693
hemorrhage - chemically induced (685) 685
risk (682) 682
acute coronary syndromes (681) 681
hematology (680) 680
aged, 80 and over (673) 673
pharmacology & pharmacy (665) 665
ticlopidine - pharmacology (665) 665
drug therapy (624) 624
myocardial-infarction (620) 620
platelet aggregation inhibitors - pharmacology (614) 614
therapy (594) 594
cardiovascular (593) 593
medicine, general & internal (572) 572
heart attacks (560) 560
retrospective studies (548) 548
follow-up studies (525) 525
acute coronary syndrome - drug therapy (523) 523
stroke (512) 512
blood platelets (501) 501
cardiac patients (501) 501
coronary heart disease (491) 491
blood platelets - drug effects (490) 490
angioplasty, balloon, coronary (484) 484
care and treatment (483) 483
drug interactions (478) 478
prasugrel (478) 478
risk assessment (476) 476
cardiology (463) 463
prevention (427) 427
mortality (422) 422
stent (417) 417
surgery (411) 411
drug-eluting stents (407) 407
platelet function tests (407) 407
thrombosis - prevention & control (405) 405
intervention (404) 404
trial (392) 392
stents - adverse effects (389) 389
aggregation (384) 384
angioplasty, balloon, coronary - adverse effects (381) 381
outcomes (374) 374
adenosine - analogs & derivatives (372) 372
analysis (363) 363
prasugrel hydrochloride (363) 363
angioplasty (360) 360
platelet reactivity (355) 355
stent thrombosis (349) 349
dose-response relationship, drug (348) 348
cardiovascular disease (347) 347
myocardial infarction - drug therapy (346) 346
randomized controlled trials as topic (346) 346
anticoagulants - therapeutic use (343) 343
thrombosis - etiology (333) 333
ticlopidine - pharmacokinetics (330) 330
inhibition (329) 329
acute coronary syndrome (328) 328
drug administration schedule (328) 328
medicine & public health (327) 327
cardiovascular diseases (324) 324
double-blind method (318) 318
acute myocardial-infarction (317) 317
transluminal angioplasty (310) 310
ticagrelor (306) 306
drug resistance (305) 305
platelet aggregation inhibitors - pharmacokinetics (302) 302
genotype (300) 300
coronary angiography (299) 299
implantation (296) 296
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5397) 5397
German (117) 117
Spanish (90) 90
French (75) 75
Japanese (58) 58
Italian (38) 38
Russian (30) 30
Chinese (20) 20
Polish (14) 14
Danish (13) 13
Swedish (11) 11
Dutch (8) 8
Norwegian (7) 7
Korean (5) 5
Turkish (4) 4
Czech (3) 3
Hebrew (3) 3
Hungarian (3) 3
Croatian (2) 2
Finnish (2) 2
Portuguese (2) 2
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs... 
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | POPULATION | SUSCEPTIBILITY | RISK | TERBINAFINE | TICLOPIDINE | HEPATITIS | CLASS-I | HEPATOTOXICITY | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | ANTIGEN | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage
Journal Article
Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1821 - 1830
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | WARFARIN | REGIMENS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2011, Volume 58, Issue 22, pp. 2263 - 2269
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with... 
Cardiovascular | Internal Medicine | non–ST-segment elevation myocardial infarction | chronic kidney disease | bleeding | ST-segment elevation myocardial infarction | unstable angina | acute coronary syndrome(s) | antiplatelet | antithrombotic | nonST-segment elevation myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | WAVE MYOCARDIAL-INFARCTION | HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | non-ST-segment elevation myocardial infarction | MOLECULAR-WEIGHT HEPARIN | PLATELET INHIBITION | DOUBLE-BLIND | ST-SEGMENT ELEVATION | STAGE RENAL-DISEASE | UNFRACTIONATED HEPARIN | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Heparin - administration & dosage | Thiophenes - administration & dosage | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - complications | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Polysaccharides - administration & dosage | Kidney Diseases - complications | Platelet Aggregation Inhibitors - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Clinical Trials as Topic | Uremia - complications | Adenosine - administration & dosage | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Ticlopidine - analogs & derivatives | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Hemorrhage - chemically induced | Chronic Disease | Care and treatment | Chronic kidney failure | Cardiac patients | Cardiology | Coronary heart disease | Health aspects | Cardiovascular agents | Medical colleges | Mortality | Heart attacks | Drug therapy | Acute coronary syndromes | Coronary vessels
Journal Article
Canadian Medical Association journal (CMAJ), ISSN 1488-2329, 2011, Volume 183, Issue 16, pp. 1835 - 1843
Background: Patients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake... 
DEPRESSION | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | ANTIDEPRESSANTS | CLOPIDOGREL | EVENTS | PROGNOSIS | DRUGS | ELDERLY-PATIENTS | ASPIRIN | Age Factors | Anemia - epidemiology | Angioplasty | Humans | Middle Aged | Citalopram - adverse effects | Male | Risk | Secondary Prevention | Sertraline - adverse effects | Peptic Ulcer - epidemiology | Adrenal Cortex Hormones - therapeutic use | Renal Insufficiency - epidemiology | Aspirin - administration & dosage | Paroxetine - adverse effects | Paroxetine - administration & dosage | Fluvoxamine - administration & dosage | Canada - epidemiology | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Heart Failure - epidemiology | Fluoxetine - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hemorrhage - epidemiology | Risk Factors | Serotonin Uptake Inhibitors - adverse effects | Anticoagulants - therapeutic use | Antihypertensive Agents - therapeutic use | Fluvoxamine - adverse effects | Ticlopidine - analogs & derivatives | Citalopram - administration & dosage | Sertraline - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Sex Factors | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Neoplasms - epidemiology | Cohort Studies | Aggregation | Complications and side effects | Blood platelets | Patient outcomes | Serotonin uptake inhibitors | Dosage and administration | Drug therapy | Hemorrhage | Heart attack | Risk factors | Studies | Side effects | Heart attacks | Inhibitor drugs | Research
Journal Article
Journal of Human Genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
Rare but severe adverse drug reactions (ADRs) are an important issue in drug development and in the proper usage of drugs during the post-approval phase... 
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | HLA CLASS-I | TOXIC EPIDERMAL NECROLYSIS | CLASS-II GENOTYPE | GENETIC SUSCEPTIBILITY | RISK-FACTOR | GENETICS & HEREDITY | GENOME-WIDE | HLA-B-ASTERISK-1502 ALLELE | JAPANESE PATIENTS | STEVENS-JOHNSON-SYNDROME | ABACAVIR HYPERSENSITIVITY | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Flucloxacillin | Risk groups | DQA1 protein | Allopurinol | Hypersensitivity | Liver | Drug development | Carbamazepine | Genetic screening | Ticlopidine | Quality of life | Side effects | Genetic markers | Abacavir | Histocompatibility antigen HLA | Index Medicus
Journal Article